UY32905A - Uso de un derivado de quinolona que contiene un grupo 7-(4-aminometil-3- oxima)pirrolidina que es capaz de inducir el factor estimulante de colonias de granulocitos para el tratamiento de la neutropenia y la recuperación de hematopoyesis - Google Patents

Uso de un derivado de quinolona que contiene un grupo 7-(4-aminometil-3- oxima)pirrolidina que es capaz de inducir el factor estimulante de colonias de granulocitos para el tratamiento de la neutropenia y la recuperación de hematopoyesis

Info

Publication number
UY32905A
UY32905A UY0001032905A UY32905A UY32905A UY 32905 A UY32905 A UY 32905A UY 0001032905 A UY0001032905 A UY 0001032905A UY 32905 A UY32905 A UY 32905A UY 32905 A UY32905 A UY 32905A
Authority
UY
Uruguay
Prior art keywords
neutropenia
treatment
recovery
granulocites
aminometil
Prior art date
Application number
UY0001032905A
Other languages
English (en)
Inventor
Park Hee Dong
Choi Ju Hyun
Park Jung Gyu
Original Assignee
Lg Life Sciences Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltda filed Critical Lg Life Sciences Ltda
Publication of UY32905A publication Critical patent/UY32905A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un compuesto antibiótico de quinolona de fórmula (1) capaz de promover la producción de G-CSF en el cuerpo y al . medicamento para el tratamiento de la neutropenia y la recuperación temprana
UY0001032905A 2009-09-28 2010-09-27 Uso de un derivado de quinolona que contiene un grupo 7-(4-aminometil-3- oxima)pirrolidina que es capaz de inducir el factor estimulante de colonias de granulocitos para el tratamiento de la neutropenia y la recuperación de hematopoyesis UY32905A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090092074 2009-09-28
KR20090092636 2009-09-29

Publications (1)

Publication Number Publication Date
UY32905A true UY32905A (es) 2011-12-01

Family

ID=43796408

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032905A UY32905A (es) 2009-09-28 2010-09-27 Uso de un derivado de quinolona que contiene un grupo 7-(4-aminometil-3- oxima)pirrolidina que es capaz de inducir el factor estimulante de colonias de granulocitos para el tratamiento de la neutropenia y la recuperación de hematopoyesis

Country Status (5)

Country Link
KR (1) KR20110034566A (es)
AR (1) AR078453A1 (es)
TW (1) TW201121965A (es)
UY (1) UY32905A (es)
WO (1) WO2011037433A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9079922B2 (en) 2011-11-08 2015-07-14 Actelion Pharmaceuticals Ltd 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives
AR096135A1 (es) 2013-05-02 2015-12-09 Actelion Pharmaceuticals Ltd Derivados de la quinolona
WO2021009212A1 (en) 2019-07-16 2021-01-21 Idorsia Pharmaceuticals Ltd Antibacterial quinolone derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017925A2 (en) * 2002-08-23 2004-03-04 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20040127403A1 (en) * 2002-09-06 2004-07-01 Francesco Parenti Methods for treating and preventing Gram-positive bacteremias

Also Published As

Publication number Publication date
KR20110034566A (ko) 2011-04-05
WO2011037433A2 (en) 2011-03-31
WO2011037433A3 (en) 2011-09-09
AR078453A1 (es) 2011-11-09
TW201121965A (en) 2011-07-01

Similar Documents

Publication Publication Date Title
IN2014MN01755A (es)
BRPI0921701B8 (pt) Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende
CO6680667A2 (es) Derivados ester de ácido borónico cíclico y sus usos terapéuticos
BR112012008889A2 (pt) compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes
IN2014MN02106A (es)
JO3111B1 (ar) ترايازولوبيريدينات مستبدلة واستخدامها كمثبطات ttk
MX2011013306A (es) Compuestos tetraciclicos.
MX378354B (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
EP2581376A4 (en) MATRINIC ACID / MATRINE DERIVATIVES AND METHODS OF PREPARATION AND USES THEREOF
BR112012012903A2 (pt) compostos de espiropiperidina
BRPI1004899B8 (pt) composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto
NI200900081A (es) Peptidommético smac útiles como inhibidores de iap
NZ627274A (en) Anesthetic compounds and related methods of use
JO3040B1 (ar) ترايازولوبيريدينات
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
BR112013007380A2 (pt) regime de administração para nitrocatecóis
IN2012DN02502A (es)
BR112015004523A2 (pt) compostos de tetraciclina
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
BR112015014433A2 (pt) compostos tricíclicos
MX2013002620A (es) Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
UY32905A (es) Uso de un derivado de quinolona que contiene un grupo 7-(4-aminometil-3- oxima)pirrolidina que es capaz de inducir el factor estimulante de colonias de granulocitos para el tratamiento de la neutropenia y la recuperación de hematopoyesis
IN2013DN02555A (es)
IN2014DN11023A (es)
AR076709A1 (es) Piperidinas sustituidas como antagonistas de par-1 y un procedimiento para su preparacion

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190222